Infect Dis Ther. 2022 Dec 21. doi: 10.1007/s40121-022-00744-3. Online ahead of print.
NO ABSTRACT
PMID:36544075 | DOI:10.1007/s40121-022-00744-3
Categories
Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection
